Nippon Shinyaku Licenses Prulifloxacin Marketing Rights To Lee’s Pharmaceutical
This article was originally published in PharmAsia News
Executive Summary
Kyoto-based Nippon Shinyaku announced March 3 a licensing agreement on antibacterial drug prulifloxacin with Hong Kong biopharmaceutical company Lee's Pharmaceutical Holdings, which gives Lee's the exclusive marketing rights in China for antibacterial drugs containing prulifloxacin. Nippon Shinyaku will receive an undisclosed upfront payment, milestone payments based on sales achievement and product royalties. An oral broad spectrum fluoroquinolone antibiotic developed by Nippon Shinyaku, prulifloxacin is marketed in Japan by Meiji Seika with the name Sword and by Angelini with the name Unidrox in Europe. (Click here for more - Japanese language